Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
Status:
Completed
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pacritinib when given together
with chemotherapy in treating patients with acute myeloid leukemia that have an abnormal
change (mutation) in the fms-related tyrosine kinase 3 (FLT3) gene. Pacritinib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as cytarabine, daunorubicin hydrochloride, and decitabine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving pacritinib and chemotherapy
may be a better treatment for acute myeloid leukemia with FLT3 mutations.